Headlands Technologies LLC Purchases Shares of 24,599 TransMedics Group, Inc. $TMDX

Key Points

• Headlands Technologies initiated a TransMedics Group position by purchasing 24,599 shares worth approximately $1.63 million. Institutional investors collectively own 99.67% of the company.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings per share of $0.44 missed the $0.50 consensus forecast.
• Analyst sentiment is mixed, with a consensus “Hold” rating and a $124.18 target price; recent price targets range from $77 to $124, while shares opened at $84.87 after a reported 4% decline.

Headlands Technologies LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 24,599 shares of the company's stock, valued at approximately $1,634,000. Headlands Technologies LLC owned 0.07% of TransMedics Group at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of TransMedics Group by 11.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company's stock worth $119,997,000 after acquiring an additional 113,817 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 50.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company's stock valued at $117,506,000 after acquiring an additional 322,353 shares during the last quarter. Geode Capital Management LLC increased its position in TransMedics Group by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company's stock valued at $99,339,000 after purchasing an additional 2,903 shares during the period. Two Sigma Investments LP increased its position in TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company's stock valued at $71,291,000 after purchasing an additional 223,409 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in TransMedics Group by 43.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company's stock worth $69,338,000 after purchasing an additional 171,810 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Insider Buying and Selling

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company's stock.

TransMedics Group Stock Down 4.0%

Shares of NASDAQ TMDX opened at $84.87 on Tuesday. The firm has a market cap of $2.93 billion, a PE ratio of 21.82 and a beta of 1.90. TransMedics Group, Inc. has a 12-month low of $60.10 and a 12-month high of $156.00. The company's fifty day simple moving average is $79.23 and its 200 day simple moving average is $93.20. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. TransMedics Group's revenue for the quarter was up 20.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.92 EPS. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Needham & Company LLC dropped their price target on shares of TransMedics Group from $142.00 to $106.00 and set a "buy" rating on the stock in a research report on Monday, August 3rd. UBS Group cut their price target on shares of TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 5th. Weiss Ratings downgraded TransMedics Group from a "hold (c)" rating to a "hold (c-)" rating in a report on Tuesday, July 28th. Zacks Research lowered TransMedics Group from a "hold" rating to a "strong sell" rating in a research report on Monday, July 6th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $124.00 price objective on shares of TransMedics Group in a research note on Tuesday, June 30th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of "Hold" and a consensus target price of $124.18.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source